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Phosphoinositide-3-kinasetranscriptional inhibition by interferon-γ (IFN-γ) are poorly understood despite
the existence of a large number of genes that are regulated in this manner and the key role of this cytokine in
inﬂammatory disorders such as atherosclerosis. We have previously identiﬁed a novel mechanism for
transcriptional inhibition by IFN-γ that involves a reduction in the binding of transcription factors Sp1 and
Sp3 to regulatory sequences in the lipoprotein lipase (LPL) gene. In the present study, we have investigated
the signalling pathways that impact on the IFN-γ-mediated regulation of Sp1/Sp3 binding and LPL gene
transcription in macrophages. The IFN-γ-mediated inhibition of LPL promoter activity was prevented by
expression of dominant negative forms of casein kinase 2 (CK2) and protein kinase B (PKB), a key
downstream component of the phosphoinositide-3-kinase (PI3K) pathway. IFN-γ activated both the catalytic
subunits of CK2 without affecting their expression. CK2 interacted with both Sp1 and Sp3 and this association
was increased by IFN-γ. Electrophoretic mobility shift assays showed that a CK2-mediated phosphorylation
of either cellular extracts or recombinant Sp1 reduced binding to the regulatory region in the LPL gene. The
action of PKB was potentially mediated through mammalian target for rapamycin proteins. Taken together,
these results suggest a key role for CK2 and PI3K signalling pathways in the IFN-γ-mediated inhibition of
macrophage LPL gene transcription through the regulation of Sp1/Sp3 binding.
© 2008 Elsevier Inc. Open access under CC BY-NC-ND license.1. IntroductionThe cytokine interferon-γ (IFN-γ) is a key regulator of the immune
and inﬂammatory responses along with many other cellular actions
during physiological and pathophysiological conditions [1]. For
example, the cytokine plays a crucial role in the pathogenesis of
atherosclerosis, an inﬂammatory disorder, by regulating the function
andproperties of all the cell types present in the vesselwall [2]. IFN-γ is
expressed at high levels in atherosclerotic lesions andmodulates foam
cell formation, recruitment of leukocytes to the activated endothelium,
and plaque stability [2]. The deﬁciency of either IFN-γ or its receptor
limits the development of atherosclerosis in murine models of this
disease whereas administration of the cytokine potentiates it [2–4].
The cellular actions of IFN-γ are characterized by dramatic changes
in gene expression [1,2]. The mechanisms by which IFN-γ induces the
expression of several genes have been extensively investigated,
leading to the identiﬁcation of the classical Janus kinase (JAK)-signal
transducer and activator of transcription (STAT) pathway [2]. However,
several studies, including gene expression proﬁling of STAT1-deﬁcient
cells, have revealed thewidespread use of additional pathways for IFN--NC-ND license.γ action [5], the nature of which remains to be deciphered in detail. In
addition, very little is currently understood about the mechanisms by
which IFN-γ inhibits gene transcription despite the existence of a large
number of genes that are regulated in this manner, several of which
have a key role in atherosclerosis. For example, gene expression
proﬁling has identiﬁed 660 geneswhose expression inmacrophages is
inhibited by IFN-γ [6]. Among these is the lipoprotein lipase (LPL) gene,
which catalyses the hydrolysis of the triacylglycerol component of
chylomicrons and very lowdensity lipoproteins, andhas been linked to
several pathophysiological conditions associatedwith perturbations in
lipid metabolism and transport, including atherosclerosis, diabetes
and obesity [7–9]. The IFN-γ-mediated suppression of LPL mRNA
expression, protein levels and enzymatic activity has been observed in
a range of macrophage sources from different species, including
human monocyte-derived macrophages [7–9].
We have previously investigated several aspects of IFN-γ signalling in
macrophages [9–11], including the mechanisms underlying transcrip-
tional inhibition using LPL as a model gene [9]. Our studies identiﬁed a
novel mechanism for transcriptional inhibition by IFN-γ whereby the
cytokine decreases the binding of Sp1 and Sp3 to three conserved
recognition sequences in the regulatory region of the LPL gene [9]. The
purpose of this study was to investigate the signalling pathways
underlying inhibition of LPL gene transcription via Sp1 and Sp3.
Fig. 1. The IFN-γ-mediated inhibition of LPL promoter activity is prevented by
expression of DN CK2. U937 cells were transfected with DN CK2-α or the control
pSG5 vector followed by the LPL promoter-luciferase construct (−31/+187 in the pGL2
Basic-luciferase plasmid) [15] and the CMV-β-galactosidase internal control. Cells were
differentiated for 12 hwith PMA (1 µM) and then either left untreated (pSG5 or DN CK2)
or incubated for 12 h with IFN-γ (pSG5+IFN or DNCK2+IFN). Luciferase activity was
normalized to β-galactosidase activity and is expressed as Relative Luciferase Activity.
The data shown are mean±SD from three independent experiments each carried out in
triplicate. ⁎ represents signiﬁcant prevention of the IFN-γ-mediated suppression of
relative luciferase activity observed in cells transfected with the pSG5 vector (Pb0.05).
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2.1. Materials
Cell lines (mouse macrophage J774.2, humanmonocytic U937) were
from the European Collection of Animal Cell Cultures. Antibodies were
from Santa Cruz Biotechnology (casein kinase 2 (CK2)-α and α′) and
Upstate Biotechnology (Sp1 and Sp3). The protein kinase B (PKB) ac-
tivity assay kit was from Cell Signalling Technology. Recombinant IFN-γ
and tumour necrosis factor-α (TNF-α) were from Peprotech, and re-
combinant Sp1 and puriﬁed CK2 enzyme were from Promega.
2.2. Cell culture
Cells were maintained in Dulbecco's modiﬁed Eagle's medium
(J744.2) or RPMI 1640 (U937) supplemented with heat-inactivated
(56 °C, 30 min) foetal calf serum, 100 U/ml penicillin and 100 µg/ml
streptomycin. The cultures were maintained at 37 °C in a humidiﬁed
atmosphere containing 5% (v/v) CO2 in air. Treatment of J774.2
macrophages with IFN-γ (1000 U/ml) or the different pharmacological
inhibitors was performed as previously described [9–14]. U937 cells
were used for all transfection assays where differentiation was
initiated using 1 µM phorbol-12-myristate-13-acetate (PMA) and
monitored by morphological analysis [9,15].
2.3. Transient transfection and reporter gene assays
Transfection of U937 cells with an LPL promoter-luciferase DNA
construct (−31 to +187) and CMV-β-galactosidase (internal control for
transfection efﬁciency) was carried out using SuperFect™ (Qiagen) as
previously described [9,15]. In experiments involving the use of
dominant negative (DN) constructs, the cells were initially transfected
with the DN expression plasmid or control vector and incubated for 8 h
before transfection of the cells with the LPL promoter-luciferase and
CMV-βgalactosidase plasmids. TheDNplasmidsusedwerepcDNA3HA-
PKB AAA from Dr. B. Hemmings (Friedrich Miescher Institute for
Biomedical Research, Basel) and pSG-CK2α-K68A from Drs. E. M.
Chambaz and C. Cochet (INSERM, Grenoble). DN PKB speciﬁes for an
inactive form of PKBα with a mutation to alanine of lysine 179 in the
ATP-binding site and threonine 308 and serine 473 that must be
phosphorylated in the active kinase. DN CK2 codes for a kinase inactive
mutant with a lysine to alanine change at residue 68 within the ATP-
binding domain.
2.4. Western blot analysis
Whole cell extracts were prepared in buffers containing phospha-
tase and protease inhibitors and used for SDS-PAGE and western blot
analysis as previously described [9–13,15].
2.5. Immunoprecipitations and CK2 activity assays
Whole cell extracts (150–300 µg) were prepared using buffers
containing phosphatase and protease inhibitors and subjected to
immunoprecipitation and in vitro kinase assays using the β-casein
substrate as previously described [10]. For CK2 assays with Sp1, 0.5 µg
of recombinant proteinwas used as a substrate instead of β-casein. For
co-immunoprecipitation assays, the immunoprecipitated proteins
were eluted using 0.1 M glycine (pH 2.5) and subjected to SDS-PAGE
and western blot analysis.
2.6. Electrophoretic mobility shift assays (EMSA)
EMSA were carried out using whole cell extracts and radiolabelled
oligonucleotides against the Sp1 binding sites in the LPL gene as
previously described [9,15].3. Results
3.1. Role for CK2 in the IFN-γ-mediated inhibition of LPL gene transcription
The murine J774.2 cell line is a useful model system for
investigating the mechanisms underlying IFN-γ regulated macro-
phage gene expression because of demonstrated conservation of
responses with primary cultures, including the action of this cytokine
on LPL [9–14]. These cells were therefore employed to delineate the
signalling pathways underlying inhibition of LPL gene transcription by
IFN-γ. Our previous published studies showed that the IFN-γ-
mediated reduction of Sp1/Sp3 binding to its recognition sequence
in the LPL gene could be attenuated by incubation of the cells with
10 µM and 40 µM of the CK2 inhibitor apigenin [9,16–19]. Subsequent
studies also found attenuationwith 20 µM apigenin (data not shown).
To corroborate that CK2 was indeed involved in the IFN-γ-mediated
suppression of LPL gene transcription, the action of a plasmid
construct specifying for a DN form of CK2-α [20] on LPL promoter
activity in transfected macrophages was analysed. This DN construct
has been used in a number of studies to demonstrate a key role of CK2
in speciﬁc responses [11,20]. Because J774.2 macrophages are difﬁcult
to transfect with exogenous DNA at high efﬁciency and as the action of
IFN-γ on LPL gene expression is conserved in a range of macrophage
sources, including primary cultures, along with other cellular systems
(e.g. renal mesangial cells) [7–9,21], the human monocytic U937 cell
line was employed for all transfection experiments. Indeed, the U937
cell line has been used extensively to delineate the regulatory
sequences required for the regulation of gene transcription in
macrophages [9,15]. The IFN-γ-mediated suppression of LPL promoter
activity observed when the cells were transfected with the control
pSG5 vector only was abrogated in cells expressing DN CK2 (Fig. 1).
The action of IFN-γ on CK2 synthesis and activity was therefore
investigated.
3.2. The action of IFN-γ on the synthesis and activity of CK2
CK2 exists as a tetramer with two main catalytic (α and α′) and
two regulatory β subunits as well as free catalytic subunits [10,22]. In
order to investigate whether IFN-γ affects the synthesis of CK2, the
levels of the α and α′ polypeptides in J774.2 cells treated with IFN-γ
were determined by western blot analysis. Sp1 and Sp3 were also
analysed for comparative purposes (Sp1 can also act as a loading
control as IFN-γ has no effect on its expression [9]). Fig. 2A shows that
Fig. 2. The effect of IFN-γ on the expression and activity of CK2 polypeptides. (A) Whole
cell extracts from J774.2 macrophages treated with IFN-γ for the indicated period of
time, or from untreated cells at 0 h and 20 h, were subjected to western blot analysis.
The position of the immunoreactive polypeptides (42 kDa for CK2-α, 45 kDa for CK2-α′,
two closely migrating proteins with a molecular mass of ~112 kDa for Sp1, and at least
four polypeptides that form two closely migrating doublets with approximate
molecular mass of 115 and 70 kDa for Sp3) [9,15] are shown. Images are representative
of three independent experiments. (B) J774.2 macrophages were left untreated or
incubated for 3 h with IFN-γ in the absence or the presence of 20 µM apigenin (Api).
Whole cell extracts were subjected to either an in vitro kinase assay using the β-casein
substrate (β-casein with the CK2 isoform used for immunoprecipitation shown in
parentheses) or western blot analysis against isoform-speciﬁc antibodies as indicated.
The result shown is representative of two independent experiments.
Fig. 3. CK2 interacts with, and phosphorylates, Sp1. (A) J774.2 macrophages were either
left untreated (−) or incubated for 3 h with IFN-γ (+). Whole cell extracts were
immunoprecipiated with anti-Sp1 or STAT1 antibodies (IP Sp1 or IP STAT1, respectively)
and subjected to western blot analysis with antibodies used for immunoprecipitation
(Sp1 or STAT1) or those against CK2-α or α′. (B) Puriﬁed rhSp1 was used as a substrate
in kinase assays with immunoprecipitated CK2-α or -α′ from J774.2 macrophages that
were either left untreated (−) or incubated with IFN-γ for 3 h (+). Reactions were
subjected to SDS-PAGE and the phosphorylation of Sp1 was assessed by autoradio-
graphy. The results shown are representative of at least three independent experiments.
Fig. 4. The effect of CK2-mediated phosphorylation on Sp1/Sp3 DNA binding. (A) Whole
cell extracts from untreated J774.2 macrophages were phosphorylated with CK2 (0.1
and 0.2 U) and used for EMSAwith radiolabelled oligonucleotides corresponding to the
+36/+90 region of the LPL gene. Extracts from cells incubated for 20 h with IFN-γ and
those from untreated cells that were subjected to the kinase reaction in the absence of
CK2 were included for comparative purposes. The results are representative of two
independent experiments. (B) Recombinant Sp1 protein was subjected to a kinase
reaction with CK2 as indicated (0.1U) and used for EMSA with radiolabelled
oligonucleotides that recognise the +9/+49 or +46/+90 regions of the LPL gene. Sp1
treated in a similar manner in the absence of CK2 was included for comparison (−). The
results are representative of three independent experiments.
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polypeptides. In contrast, consistent with our previous studies [9],
IFN-γ reduced the polypeptide levels of Sp3 but not Sp1 (Fig. 2A).
Our previous studies on the action of IFN-γ on CK2 activation,
which was restricted to the α isoform and a single time point (3 h)
[10], showed a dramatic increase in activity following stimulation of
the cells with this cytokine. Preliminary time course experiments
showed that the activity of both CK2 catalytic subunits was induced
within 1 h of incubation of the cells with IFN-γ, peaked at 3 h and was
sustained, albeit at reduced levels, for 12–20 h (data not shown). In
order to conﬁrm the inhibitory action of apigenin, its effect on the IFN-
γ-induced activity of both the catalytic subunits at 3 h was
determined. Fig. 2B shows that, consistent with previous studies
[e.g. [10,16–19]], apigenin indeed abolishes CK2 activity of both
subunits without affecting the expression of the polypeptides.
3.3. CK2 associates with, and phosphorylates, Sp1
Our subsequent studies focused on the interaction and action of
CK2 on Sp1 because preliminary co-transfection assays showed that
Sp1, but not Sp3, was the main activator of the LPL promoter (data not
shown). We investigated the interaction of CK2 subunits with Sp1 by
co-immunoprecipitation assays. STAT1 was included for comparative
purposes. Thus, Sp1 or STAT1 was immunoprecipitated from extracts
of J774.2 macrophages that had either been left untreated or
stimulated with IFN-γ for 3 h, a period corresponding to dramaticactivation of CK2. The immunoprecipitated protein was then sub-
jected towestern blot analysis with antibodies against itself or that for
CK2-α or α′. Fig. 3A shows that Sp1 interacted with both the catalytic
Fig. 5. The effect of IFN-γ on PKB activity in J774.2 macrophages. The cells were treated
with IFN-γ (+IFN-γ) for the indicated period of time (untreated cells (−IFN-γ) at 0 h and
20 h were included for comparative purposes). PKB was immunoprecipitated from
whole cell extracts and subjected to a kinase assay in which its ability to phosphorylate
the downstream target GSKwas analysed. The levels of phospho-GSK3-α/β (Ser 21/9) in
the kinase assay and total PKB in cell extracts were determined bywestern blot analysis.
The results are representative of three independent experiments.
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with IFN-γ. A similar proﬁle was observed when the analysis was
performed with the Sp3 antibody (Supplementary material, Fig. 1). In
contrast, no interaction was seen between STAT1 and the CK2
polypeptides (Fig. 3A).
The kinase assays presented in Fig. 2B used the classical β-casein as a
substrate. The assaywas therefore repeatedwith recombinant humanSp1
(rhSp1) produced in Sf9 cells using a baculovirus expression system
(Promega). The activity of CK2-α or -α′ in terms of their ability to
phosphorylate rhSp1wasalso inducedby IFN-γ (Fig. 3B). Twopolypeptide
species of 82 kDa and 57 kDa for rhSp1were observed in this assay, which
migrated at an apparently lower molecular weight, due to the lesser
extent of glycosylation in Sf9 cells than in mammalian cells (Promega).
3.4. CK2-mediated phosphorylation of Sp1 is associated with decreased
DNA binding
To further investigate the potential impact of CK2-mediated
phosphorylation of Sp1 on DNA binding activity, experiments were
carried out using puriﬁed CK2. Firstly, the effect of CK2-mediated
phosphorylation of extracts from untreated macrophages on Sp1/Sp3
binding was analysed by EMSA. The probe used corresponded to the
+36/+90 region of the LPL gene [15] and contained all three Sp1/Sp3
binding sites. Consistent with our previous studies [9,15], three DNA-
protein complexes were produced (C1 to C3; Fig. 4A). Antibody
interference assays have shown that complex C1 is composed of Sp1
whereas complexes C2 and C3 consist mainly of Sp3 [9,15]. Phosphor-
ylation of extracts from untreated cells with two different concentra-
tions of CK2 reduced the binding of Sp1/Sp3 to levels observed in IFN-Fig. 6. The effect of DN PKB on the IFN-γ-mediated decrease in LPL promoter activity.
U937 cells were transfected with the control pcDNA3 vector or DN PKB followed by the
LPL promoter-luciferase construct (−31/+187 in the pGL2 Basic-luciferase plasmid) [15].
Cells were then differentiated for 12 h with PMA (1 µM) and either left untreated
(pcDNA or DN PKB) or incubated for 12 h with IFN-γ (pcDNA+IFN or DN PKB+IFN).
Luciferase activity was normalized to total protein concentration and is expressed as
Relative Luciferase Activity. The data shown are mean±SD from three independent
experiments each carried out in triplicate. ⁎ represents signiﬁcant prevention of the
IFN-γ-mediated suppression of relative luciferase activity observed in cells transfected
with the pcDNA3 vector (Pb0.05).γ-treated cells (Fig. 4A). Similar results were obtained when probes
containing regions +9/+49 (single Sp1/Sp3 binding site) and +46/+90
(two Sp1/Sp3 binding sites) [9] were employed (Supplementary
material, Fig. 2). Furthermore, the binding of rhSp1 to the +9/+49
and the +46/+90 regions was decreased by phosphorylation with
puriﬁed CK2 (Fig. 4B).
3.5. The phosphoinositide-3-kinase (PI3K) pathway is also involved in
the regulation of LPL gene transcription through Sp1/Sp3
Our previous studies showed that the PI3K inhibitor wortmannin
prevented, at least in part, the IFN-γ-mediated inhibition of LPL
enzymatic activity and mRNA expression in J774.2 macrophages [14].
More recently, we have shown that PI3K, along with CK2, is involved in
the classical JAK-STAT pathway of IFN-γ signalling through the
regulation of STAT1 phosphorylation at serine 727, which is necessary
for maximal transcriptional activity [11]. PKB (also called Akt) is a key
downstreammediator of PI3Kactivation [23]. The actionof IFN-γonPKB
activity in J774.2 macrophages was therefore investigated using an in
vitrokinase assay inwhich its ability tophosphorylate glycogen synthaseFig. 7. The potential role of the different signalling pathways in the IFN-γ-mediated
decrease in Sp1/Sp3 binding. J774.2 macrophages were either left untreated (−) or
incubated for 20 h with IFN-γ (+) in the absence or the presence of the indicated
inhibitors: A. LY294002 (0.05 µM, 0.5 µM and 5 µM); B. SB415286 (5 µM, 25 µM and
50 µM); C. AG490 (5 µM, 50 µM and 150 µM); and D. rapamycin (100 nM, 500 nM and
1 µM). Whole cell extracts were subjected to EMSA using radiolabelled oligonucleotides
that recognise the +9/+49 and the +46/+90 regions of the LPL gene. The results shown
are representative of two to three independent experimental series.
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other cellular systems [24–26], IFN-γ activated PKB in J774.2 macro-
phages (Fig. 5). In order to ascertain whether PKB affects LPL gene
transcription, the effect of DN PKB on LPL promoter activity in
transfected cells was analysed. Fig. 6 shows that the IFN-γ-mediated
decrease in LPL promoter activity could be prevented by expression of
DN PKB.
To determine whether the PI3K pathway was also involved in the
cytokine-mediated reduction of Sp1/Sp3 binding to its recognition
sequence in the LPL gene, the effect of pre-treatment of the cells with
three different concentrations of the PI3K inhibitor LY294002 on the
IFN-γ-mediated decrease in Sp1/Sp3 binding was analysed by EMSA.
Representative, comparative experiments were also carried out with
SB415286, an inhibitor of GSK, as we found that IFN-γ had no effect on
phosphorylation-mediated activation of GSK-3β or serine 9 (data not
shown). Fig. 7A shows that the presence of LY294002 attenuated the
IFN-γ-mediated reduction of Sp1/Sp3 binding to the LPL gene. Such an
effect was not observedwith the GSK inhibitor SB415286 (Fig. 7B). Our
previous studies showed that the IFN-γ-mediated activation of PKB
could be attenuatedby inhibition of the PI3Kpathwayand JAK2but not
by CK2 [11]. Indeed, co-immunoprecipitation assays demonstrated a
constitutive interaction between JAK2 and the p85 subunit of PI3K
(data not shown). Consistent with such an interaction, inclusion of the
JAK2 inhibitor, AG490, at three different concentrations, prevented the
IFN-γ-mediated suppression of Sp1/Sp3 binding (Fig. 7C).
PKB-mediated phosphorylation of rhSp1 had no effect on DNA
binding (data not shown), thereby suggesting that a downstream
kinase(s) was potentially mediating the actions of PKB on Sp1/Sp3Fig. 8. Theaction of IFN-γ andTNF-αon Sp1/Sp3binding. (A) J774.2macrophageswere left
untreated (−) or incubated for 20 h with the indicated concentration of TNF-α. (B) Cells
were either left untreated or incubated for 20 h with 50 U/ml IFN-γ or 15 U/ml TNF-α,
either alone or in combination as shown.Whole cell extractswere subjected to EMSAusing
radiolabelledoligonucleotides that correspond to the +9/+49or+46/+90 regionsof the LPL
gene. The results are representative of three independent experimental series.binding. The mammalian targets of rapamycin (mTOR) proteins
represent an important class of downstream targets of PKB, which
have been implicated in the control of several cellular functions [27].
The action of the mTOR inhibitor rapamycin was therefore analysed.
As shown in Fig. 7D, rapamycin attenuated the decrease in Sp1/Sp3
binding.
3.6. The synergism between IFN-γ and TNF-α on LPL gene transcription
is not mediated at the level of Sp1/Sp3 DNA binding
Interactions between cytokines in the regulation of macrophage
function are relatively common and our previous studies showed a
synergistic action of IFN-γ and TNF-α on the expression of LPL mRNA,
protein and enzymatic activity [13]. Because this synergism was
mediated at the level of gene transcription [28], we wondered whether
this occurred at the level of Sp1/Sp3 binding to the LPL gene. Indeed, a
recent study has shown that the suppression of sodium–hydrogen
exchanger-3 expression by both IFN-γ and TNF-α is mediated through
decreased binding of Sp1 and Sp3 [29]. In addition, the TNF-α-mediated
downregulation of murine growth hormone receptor expression has
been shown to be due to inhibition of Sp1 and Sp3 binding [30]. EMSA
were therefore performed using extracts from J774.2 macrophages that
hadeither been left untreatedor exposed toTNF-α, IFN-γ, or bothTNF-α
and IFN-γ, and radiolabelled oligonucleotides corresponding to the
+9/+49 or +46/+90 region of the LPL gene. Several different concentra-
tions of TNF-α, which were active in suppressing another response in
the laboratory (C/EBP-α promoter activity in Hep3B cells), did not
reduce binding by Sp1/Sp3 (Fig. 8A). In addition, the IFN-γ-mediated
reduction in the binding of Sp1/Sp3 was not enhanced by TNF-α
(Fig. 8B). The concentrations of these two cytokines used corresponded
to those that produced a marked synergism at the level of LPL mRNA
expression and enzymatic activity [13].
4. Discussion
The cytokine IFN-γ is a key regulator of the immune and
inﬂammatory response and plays a crucial role in the pathogenesis
of atherosclerosis [2]. The cellular actions of IFN-γ are associated
with both the activation and the inhibition of gene transcription
[2,5,6,9–11]. However, the mechanisms underlying the IFN-γ-
mediated inhibition of gene transcription are poorly understood
despite 25% of the macrophage transcriptome being regulated in this
manner [6]. Our previous studies using LPL as a model gene identiﬁed
a novel pathway involving the IFN-γ-mediated decrease in Sp1/Sp3
binding to regulatory sequences in the gene [9]. The studies presented
here provide insights into the signalling pathways underlying such
regulation and reveal potentially key roles for CK2 and the PI3K/PKB/
mTOR pathways in the inhibition of gene transcription by IFN-γ.
CK2 phosphorylates serine or threonine residues in acidic domains
with (S/T)XX(D/E) being the canonical motif [22]. The constitutive
activity of CK2 is stimulated further by several extracellular mediators
[10,22]. A number of recent studies have suggested a potentially
important role for CK2 in the control of the inﬂammatory response
[22]. For example, inhibition of CK2 has been shown to reduce pain-
related behaviors in murine models of acute and chronic inﬂamma-
tory pain [31]. In addition, in a rat model of glomerulonephritis, which
similar to atherosclerosis is an inﬂammatory disorder, the progression
of the disease could be prevented by administration of either
antisense oligodeoxynucleotides against CK2 or inhibitors such as
apigenin [32]. CK2 is indeed a major regulator of nuclear factor-кB
(NF-кB), a key transcription factor in signalling by pro-inﬂammatory
cytokines such as interleukin-1 and TNF-α [22,33]. Our recent studies
have revealed a potentially important role for CK2 in IFN-γ signalling
[10,11]. Thus, the IFN-γ-induced expression of the inducible cAMP
early repressor (ICER), a transcriptional inhibitor, was mediated via
stimulation of CK2-α activity leading to the activation of transcription
2301S.M. Harris et al. / Cellular Signalling 20 (2008) 2296–2301factors belonging to the cAMP response element binding protein
family, which bind to regulatory sequences in the ICER gene promoter
[10]. More recently, we have shown a key role for CK2 in the IFN-γ-
induced expression of several genes implicated in atherosclerosis that
are known targets of the classical JAK-STAT pathway [11]. CK2
regulates the phosphorylation of STAT1 at serine 727 in macrophages
[11]. We have now extended these ﬁndings to indicate a role of CK2 in
transcriptional suppression by IFN-γmediated via phosphorylation of
Sp1 (and possibly Sp3), which leads to decreased binding to regulatory
sequences in the LPL gene. Transcriptional inhibition that is
potentially mediated by a CK2-mediated phosphorylation of Sp1 has
also been suggested for the ﬂow-dependent suppression of endothe-
lial Toll-like receptor 2 expression [34]. Indeed, CK2-mediated
phosphorylation of the carboxyl terminus of Sp1 is associated with a
decrease in its DNA binding activity [35].
An increasing body of evidence supports a role for the PI3K pathway
in IFN-γ signalling and our previous studies have revealed a key function
in the regulation of a largenumberof genes implicated in atherosclerosis
[11]. Deletion of the PI3Kγ gene has been demonstrated to attenuate
atherosclerosis in apolipoprotein E-deﬁcient mice, a mouse model for
this disease [36]. A large number of genes regulated by IFN-γ through
PI3K signalling are known targets for the JAK/STATpathway [11]. Indeed,
the action of PI3K in these cases appears to be mediated, at least in part,
through the regulation of STAT1 serine 727 phosphorylation [11]. The
studies presented here extend the role of PI3K in IFN-γ signalling to
transcriptional suppression by this cytokine through Sp1/Sp3. A
potential role for mTOR was identiﬁed as pre-treatment of the cells
with rapamycin attenuated the IFN-γ-mediated reduction in Sp1/Sp3
binding. The PI3K/mTOR pathway has previously been implicated in the
insulin-mediated increase in LPL activity in adipocytes [37], and our
studies extend this to transcriptional inhibition through Sp1/Sp3. The
precise mechanisms underlying such regulation remain to be deter-
mined but could include direct phosphorylation-mediated reduction of
Sp1 binding. In addition, as mTOR is also associated with translational
regulation [24,27], it could potentially be involved in the reduction of
Sp3 polypeptide levels observed when the cells are treated with IFN-γ.
Interestingly, a recent study investigating the mechanisms underlying
the PI3K-mediated suppression of PMA-induced expression of
p21WAF1/Cip1 showed that blocking of the PI3K/mTOR pathway was
associatedwith increased binding by Sp1 [38]. Such amechanismmight
therefore be common in transcriptional inhibition through Sp1/Sp3.
In conclusion, our studies provide novel insights into the role and
mechanism of action of CK2 and PI3K signalling in the IFN-γ-mediated
suppression of LPL gene transcription. Although IFN-γ regulates gene
transcription mainly through the JAK-STAT pathway, several studies
have indicated the existence of alternative pathways. The CK2- and
PI3K-mediated regulation of Sp1/Sp3 binding could represent one
such mechanism.
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